Function of β2-Adrenergic Receptors in Chronic Localized Myalgia

Aims: To investigate alteration of β2-adrenergic receptor (β2AR) function in chronic localized myalgia subjects by evaluating levels of the β2AR second messenger, cyclic adenosine monophosphate (cAMP), in mononuclear cells after βAR-agonist stimulation. Methods: Eleven chronic localized myalgia subjects and 21 matched healthy controls participated in this study. Peripheral blood (30 cc) was drawn from the subjects’ anterocubital vein. Mononuclear cells were isolated from the total blood by using the Ficoll-Hypaque gra-dient technique. Basal and stimulated intracellular cAMP levels were determined by enzyme immunoassay using a commercially available kit. Aliquots of 5 × 106 cells were incubated with or with-out stimulation of the βAR-agonist isoproterenol for 5 minutes. Five different concentrations of isoproterenol (10–3M to 10–7M) were utilized. cAMP levels in both groups were tested statistically by a 2-way repeated-measures ANOVA with 2 predictors, group difference and isoproterenol concentration difference. As with iso-proterenol stimulation, the cAMP responses to forskolin, which activates adenylyl cyclase directly and produces cAMP, bypassing the cell surface receptors were also measured. Results: The basal cAMP levels in both groups (myalgia: 0.33 ± 0.02 pmol/5 × 106 cells; control: 0.43 ± 0.10 pmol/5 × 106 cells) were almost identi-cal, and isoproterenol-produced cAMP levels increased dose-depen-dently in both groups. No significant differences in the mean cAMP levels were observed between the groups (P = .909). Significant increases were observed according to the isoproterenol concentra-tion increase (P ＜ .0001). The cAMP responses to forskolin stimu-lation also showed no significant group difference (P = .971). Conclusion: These results suggest that β2AR function is not different between localized myalgia subjects and healthy individuals.

localized myalgia; β2-adrenergic receptor; cAMP; mononuclear cell; isoproterenol

1. Svensson P, Graven-Nielsen T. Craniofacial muscle pain: Review of mechanisms and clinical manifestations. J Orofac Pain 2001;15:117–145.

2. Lund N, Bengtsson A, Thorborg P. Muscle tissue oxygen pressure in primary fibromyalgia. Scand J Rheumatol 1986;15:165–173.

3. Delcanho RE, Kim YJ, Clark GT. Haemodynamic changes induced by submaximal isometric contraction in painful and non-painful human masseter using near infrared spectroscopy. Arch Oral Biol 1996;41:585–596.

4. Elam M, Johansson G, Wallin BG. Do patients with primary fibromyalgia have an altered muscle sympathetic nerve activity? Pain 1992;48:371–375.

5. Mense S, Stahnke M. Responses in muscle afferent fibers of slow conduction velocity to contractions and ischemia in the cat. J Physiol 1983;342:383–397.

6. Acero CO Jr, Kuboki T, Maekawa K, Yamashita A, Clark GT. Haemodynamic responses in chronically painful, human trapezius muscle to cold pressor stimulation. Arch Oral Biol 1999;44:805–812.

7. Maekawa K, Kuboki T, Miyawaki T, Shimada M, Yamashita A, Clark GT. Effect of intravenous infusion of a beta-adrenergic blocking agent on the haemodynamic changes in human masseter muscle induced by cold-pressor stimulation. Arch Oral Biol 1999;44:475–483.

8. Guimaraes S, Moura D. Vascular adrenoceptors: An update. Pharmacol Rev 2001;53:319–356.

9. Summers RJ, Kompa A, Roberts SJ. Beta-adrenoceptor subtypes and their desensitization mechanisms. J Auton Pharmacol 1997;17:331–343.

10. Johnson M. The beta-adrenoceptor. Am J Respir Crit Care Med 1998;158:S146–S153.

11. Maekawa K, Clark GT, Kuboki T. Intramuscular hypoperfusion, adrenergic receptors and chronic muscle pain. J Orofac Pain 2002;3:251–260.

12. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160–172.

13. Headache classification committee of the international headache society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):19–34.

14. Svetkey LP, Timmons PZ, Emovon O, Anderson NB, Preis L, Chen YT. Association of hypertension with beta2- and alpha2c10-adrenergic receptor genotype. Hypertension 1996;27:1210–1215.

15. Rosmond R, Ukkola O, Chagnon M, Bouchard C, Bjorntorp P. Polymorphisms of the beta2-adrenergic receptor gene (ADRB2) in relation to cardiovascular risk factors in men. J Intern Med 2000;248:239–244.

16. Ishiyama-Shigemoto S, Yamada K, Yuan X, Ichikawa F, Nonaka K. Association of polymorphisms in the beta2-adrenergic receptor gene with obesity, hypertriglyceridaemia, and diabetes mellitus. Diabetologia 1999;42:98–101.

17. Boyüm A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 1968;97:77–89.

18. Seamon K, Daly JW. Activation of adenylate cyclase by the diterpene forskolin does not require the guanine nucleotide regulatory protein. J Biol Chem 1981;256: 9799–9801.

19. Insel PA, Motulsky HJ, Mahan LC. Regulation of cyclic AMP accumulation in lymphoid cells. Proc Soc Exp Biol Med 1985;179:472–478.

20. Lefkowitz RJ, Caron MG, Stiles GL. Mechanisms of membrane-receptor regulation. Biochemical, physiological, and clinical insights derived from studies of the adrenergic receptors. N Engl J Med 1984;310:1570–1579.

21. Maekawa K, Twe C, Lotaif A, Chiappelli F, Clark GT. Function of beta-adrenergic receptors on mononuclear cells in patients with fibromyalgia. Preliminary report. J Rheumatol 2003;30:364–368.